IRIS
SVICHER, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 43.233
AS - Asia 7.574
EU - Europa 6.125
SA - Sud America 1.136
AF - Africa 151
OC - Oceania 107
Continente sconosciuto - Info sul continente non disponibili 16
Totale 58.342
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 43.015
SG - Singapore 4.067
CN - Cina 1.267
IT - Italia 1.098
BR - Brasile 932
RU - Federazione Russa 818
DE - Germania 816
HK - Hong Kong 663
VN - Vietnam 567
UA - Ucraina 511
FR - Francia 486
SE - Svezia 452
IE - Irlanda 451
PL - Polonia 394
FI - Finlandia 375
GB - Regno Unito 318
KR - Corea 242
JP - Giappone 229
IN - India 127
CA - Canada 119
AU - Australia 100
NL - Olanda 87
ES - Italia 86
AR - Argentina 72
MX - Messico 61
ID - Indonesia 60
BD - Bangladesh 55
BE - Belgio 51
TR - Turchia 51
AT - Austria 47
CZ - Repubblica Ceca 47
IQ - Iraq 44
ZA - Sudafrica 42
CO - Colombia 34
EC - Ecuador 33
PH - Filippine 28
MA - Marocco 20
PK - Pakistan 20
CL - Cile 18
UZ - Uzbekistan 18
VE - Venezuela 18
CH - Svizzera 16
AE - Emirati Arabi Uniti 15
KE - Kenya 15
IL - Israele 13
EG - Egitto 12
RO - Romania 12
JM - Giamaica 11
LT - Lituania 11
NG - Nigeria 11
PE - Perù 11
MY - Malesia 10
PY - Paraguay 10
SA - Arabia Saudita 10
TN - Tunisia 10
TW - Taiwan 10
DZ - Algeria 9
EU - Europa 9
JO - Giordania 9
KZ - Kazakistan 8
NP - Nepal 8
IR - Iran 7
NZ - Nuova Zelanda 7
OM - Oman 7
PT - Portogallo 7
TH - Thailandia 7
BG - Bulgaria 5
DK - Danimarca 5
ET - Etiopia 5
UY - Uruguay 5
AL - Albania 4
AO - Angola 4
BB - Barbados 4
CM - Camerun 4
DO - Repubblica Dominicana 4
GR - Grecia 4
GT - Guatemala 4
HN - Honduras 4
KG - Kirghizistan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BO - Bolivia 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
GE - Georgia 3
KH - Cambogia 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
MN - Mongolia 3
PS - Palestinian Territory 3
QA - Qatar 3
RS - Serbia 3
UG - Uganda 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AZ - Azerbaigian 2
CG - Congo 2
GH - Ghana 2
HR - Croazia 2
Totale 58.308
Salva come PNG Salva come JPEG
Città #
Woodbridge 11.094
Wilmington 10.917
Houston 8.877
Singapore 1.953
Fairfield 1.442
Ashburn 964
Ann Arbor 913
San Jose 883
Chandler 840
Hong Kong 649
Seattle 586
Beijing 525
Cambridge 460
Jacksonville 419
Dublin 398
Rome 394
Kraków 324
New York 315
Council Bluffs 298
Medford 283
Dearborn 275
Santa Clara 273
Helsinki 248
Los Angeles 231
The Dalles 226
Tokyo 192
Ho Chi Minh City 187
Hanoi 146
Milan 143
Lawrence 135
Buffalo 117
Munich 111
Moscow 109
San Diego 99
São Paulo 96
Dallas 95
Menlo Park 85
Nuremberg 81
Lauterbourg 77
Orem 69
Mülheim 65
Chicago 60
London 60
Zhengzhou 60
San Francisco 58
Brussels 50
Warsaw 48
Jakarta 46
Phoenix 45
Creede 44
Chennai 40
Denver 38
Brooklyn 37
Stockholm 37
Boardman 36
Palo Alto 36
Montreal 35
Redondo Beach 34
Frankfurt am Main 33
Sydney 33
Poplar 32
Engelhard 31
Melbourne 31
Toronto 31
North Bergen 30
La Veta 29
Amsterdam 28
Dong Ket 28
Rio de Janeiro 28
Johannesburg 27
Atlanta 26
Brno 25
University Park 25
Guangzhou 24
Haiphong 24
Redwood City 24
Cedarhurst 23
Vienna 23
Canberra 22
Mexico City 22
Boston 21
Falls Church 21
Lappeenranta 21
Nanjing 21
Verona 21
Washington 21
Naples 20
Olomouc 20
Da Nang 19
Madrid 19
Shanghai 19
Bari 18
Colorado Springs 18
Manchester 18
Curitiba 17
Baghdad 16
Biên Hòa 16
Hefei 16
Mumbai 16
Tashkent 16
Totale 47.331
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 577
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 574
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 568
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 547
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 532
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 527
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 518
Therapeutic strategies towards HIV-1 infection in macrophages 510
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 507
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 504
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence 493
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008 490
Understanding HIV compartments and reservoirs 488
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 487
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 485
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 484
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies 479
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 478
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 478
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 477
Novel drug resistance mutations in HIV: Recognition and clinical relevance 475
HIV-1-associated dementia during HAART therapy 475
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 474
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 474
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 474
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 473
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 473
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 472
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 468
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis 464
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 463
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 461
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 458
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 457
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 455
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 454
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 452
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 450
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 450
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 447
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 444
Incomplete APOBEC3G/F neutralization by HIV-1 Vif mutants facilitates the genetic evolution from CCR5 to CXCR4 usage 444
Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme 443
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 442
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 440
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 439
Complete hbv prophylaxis withdrawal in HBsAg-positive liver transplant recipients after long-term minimal immunosuppression 439
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 438
Dynamics of NRTI resistance mutations during therapy interruption 435
Molecular dynamics and free energy studies on the wild-type and mutated hiv-1 protease complexed with four approved drugs: Mechanism of binding and drug resistance 434
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 434
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes 434
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 433
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 433
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 432
Highlights on HIV eradication in 2013 429
Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage 428
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 427
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 427
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 426
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 424
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations 424
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 422
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 421
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 421
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 420
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 418
Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE) 418
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 416
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 415
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 414
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 413
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 410
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 409
The role of HIV infection in neurologic injury 409
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 407
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B 407
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors 406
Dual mixed (but not X4) tropic-HIV-1 isolates can replicate in human primary macrophages and are inhibited by CCR5- inhibitors 406
Does residual virus replication during successful HAART lead to HIV-1 genetic evolution? 405
Temporal change in the use of genotypic resistance testing over the years 1999--2003 405
HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. 403
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 402
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. 399
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 398
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 398
The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype 397
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 392
Impact of pre-therapy viral load on virological response to modern first-line HAART 388
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 387
Selected Amino Acid Mutations in HIV-1 B Subtype gp41 are Associated with Specific gp120v3 Signatures in the Regulation of Co-Receptor Usage 384
Papillomavirus and cervical cancer: Epidemiology, genetics and prevention [Il papillomavirus umano e il cancro della cervice uterina: Epidemiologia, basi genetiche e prevenzione] 379
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 379
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 379
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 376
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 372
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 364
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. 361
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 360
CCR5/CXCR4 dual antagonism for the improvement of HIV infection therapy 359
Totale 44.140
Salva come PNG Salva come JPEG
Categoria #
all - tutte 144.310
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 144.310
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021363 0 0 0 0 0 0 0 0 0 0 249 114
2021/20221.877 114 141 118 97 80 163 86 78 365 145 74 416
2022/20232.309 250 196 145 267 192 465 162 225 182 33 155 37
2023/20241.272 223 35 113 61 123 198 62 24 77 142 25 189
2024/20255.937 175 1.071 499 344 221 396 567 260 616 332 751 705
2025/20269.156 890 421 926 913 945 451 1.269 1.255 1.201 858 27 0
Totale 59.213